Abstract
We tracked the effective reproduction number Rt of SARS-CoV-2 Omicron BF.7 in Beijing in November – December 2022 by fitting a transmission dynamic model parameterized with real-time mobility data to (i) the daily number of new symptomatic cases on November 1-11 (when the zero-covid interventions were still strictly enforced) and (ii) the proportion of individuals who participated in online polls on December 10-22 and self-reported to have been previously test-positive since November 1. After the announcement of “20 measures”, we estimated that Rt increased to 3.44 (95% CrI: 2.82 – 4.14) on November 18 and the infection incidence peaked on December 11. The cumulative infection attack rate (i.e. the proportion of population who have been infected since November 1) was 43.1% (95% CrI: 25.6 – 60.9) on December 14 and 75.7% (95% CrI: 60.7 – 84.4) on December 22. Surveillance programmes should be rapidly set up to monitor the evolving epidemiology and evolution of SARS-CoV-2 across China.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was supported by Health and Medical Research Fund (grant no.: 21200122, CID-HKU2 and COVID19F05), Health and Medical Research Fund Research Fellowship Scheme (grant no.: 06200097), General Research Fund (grant no.: 17110020), and the AIR@InnoHK administered by Innovation and Technology Commission of The Government of the Hong Kong Special Administrative Region. KL was supported by the Enhanced New Staff Start-up Research Grant from LKS Faculty of Medicine, The University of Hong Kong. The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
We collated all data from publicly available data sources. All data included in the analyses are available in the main text or the supplementary materials.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
We have expanded the analysis to fit the model to more data and estimated the cumulative IAR has reached 75.7% (95% CrI: 60.7-84.4) on December 22.
Data Availability
We collated all data from publicly available data sources. All data included in the analyses are available in the main text or the supplementary materials.
